ENHERTU followed by THP approved in China as the first and only HER2 directed ADC...

Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC

RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially...

Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519

Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC,...

NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development